Ernexa Therapeutics has a calendar for ERNA-101, and it has been fairly consistent. The IND application goes in during the third quarter of 2026. The first-in-human Phase 1 study follows in the fourth, in patients with platinum-resistant ovarian cancer.
That is the company’s own timetable, laid out in a March 31 business update. Ernexa also listed what comes after: an initial clinical data readout in the first half of 2027, then a move into Phase 2 in the second half of 2027 with a possible co-development partner.
Under the hood
ERNA-101 is a synthetic cell therapy built from induced mesenchymal stem cells, or iMSCs. Ernexa starts with reprogrammed induced pluripotent stem cells and engineers them to find tumors and release immune-activating cytokines on site. The aim is to turn immunologically “cold” tumors into ones the immune system responds to. Because the cells are allogeneic, no patient-specific harvesting is needed.
The evidence so far is preclinical. In a syngeneic ovarian cancer model, ERNA-101 combined with an anti-PD-1 antibody produced durable antitumor activity, high rates of complete tumor regression and longer survival. The combination did better than either agent alone, the company said.
Regulators and money
On Jan. 6, Ernexa announced it had finished a Pre-IND meeting with the FDA. The company said the agency’s feedback gave it “strong regulatory alignment” on its development approach, and that tech transfer for clinical manufacturing was already underway. The March update also listed clinical manufacturing process development for Q2 2026 and release of a first product batch in Q3.
CEO Sanjeev Luther called the coming year “a transformative period” as Ernexa moves from a preclinical organization into a clinical-stage one. The company says a recent $10.5 million financing supports that plan, and that it cut general and administrative expenses by about 61% year over year.
Ernexa has released no human data on ERNA-101. The company also runs a second program, ERNA-201, an anti-inflammatory iMSC therapy aimed at autoimmune disease including rheumatoid arthritis, with its own FDA pre-IND meeting planned for the fourth quarter. Consult your doctor for medical advice.
Sources
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
- Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
